FGF23 Synthesis and Activity.

Current molecular biology reports Pub Date : 2019-03-01 Epub Date: 2019-01-17 DOI:10.1007/s40610-019-0111-8

Megan L Noonan, Kenneth E White

{"title":"FGF23 Synthesis and Activity.","authors":"Megan L Noonan, Kenneth E White","doi":"10.1007/s40610-019-0111-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: The phosphaturic hormone FGF23 is produced primarily in osteoblasts/osteocytes and is known to respond to increases in serum phosphate and 1,25(OH)2 vitamin D (1,25D). Novel regulators of FGF23 were recently identified, and may help explain the pathophysiologies of several diseases. This review will focus on recent studies examining the synthesis and actions of FGF23.Recent findings: The synthesis of FGF23 in response to 1,25D is similar to other steroid hormone targets, but the cellular responses to phosphate remain largely unknown. The activity of intracellular processing genes control FGF23 glycosylation and phosphorylation, providing critical functions in determining the serum levels of bioactive FGF23. The actions of FGF23 largely occur through its co-receptor αKlotho (KL) under normal circumstances, but FGF23 has KL-independent activity during situations of high concentrations.Summary: Recent work regarding FGF23 synthesis and bioactivity, as well as considerations for diseases of altered phosphate balance will be reviewed.","PeriodicalId":72737,"journal":{"name":"Current molecular biology reports","volume":"5 1","pages":"18-25"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469709/pdf/nihms-1524962.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular biology reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40610-019-0111-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The phosphaturic hormone FGF23 is produced primarily in osteoblasts/osteocytes and is known to respond to increases in serum phosphate and 1,25(OH)₂ vitamin D (1,25D). Novel regulators of FGF23 were recently identified, and may help explain the pathophysiologies of several diseases. This review will focus on recent studies examining the synthesis and actions of FGF23.

Recent findings: The synthesis of FGF23 in response to 1,25D is similar to other steroid hormone targets, but the cellular responses to phosphate remain largely unknown. The activity of intracellular processing genes control FGF23 glycosylation and phosphorylation, providing critical functions in determining the serum levels of bioactive FGF23. The actions of FGF23 largely occur through its co-receptor αKlotho (KL) under normal circumstances, but FGF23 has KL-independent activity during situations of high concentrations.

Summary: Recent work regarding FGF23 synthesis and bioactivity, as well as considerations for diseases of altered phosphate balance will be reviewed.

查看原文本刊更多论文

FGF23 的合成与活性。

综述目的：磷酸化激素 FGF23 主要在成骨细胞/骨细胞中产生，已知会对血清磷酸盐和 1,25(OH)2 维生素 D（1,25D）的增加做出反应。最近发现了 FGF23 的新型调节因子，它们可能有助于解释多种疾病的病理生理。本综述将重点介绍最近对 FGF23 的合成和作用进行的研究：FGF23对1,25D的合成反应与其他类固醇激素靶点相似，但细胞对磷酸盐的反应在很大程度上仍然未知。细胞内加工基因的活性控制着 FGF23 的糖基化和磷酸化，在决定血清中生物活性 FGF23 水平方面发挥着关键作用。在正常情况下，FGF23的作用主要通过其共同受体αKlotho（KL）来实现，但在高浓度情况下，FGF23具有不依赖于KL的活性：将对有关 FGF23 合成和生物活性的最新研究成果以及对磷酸盐平衡改变的疾病的考虑进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current molecular biology reports

自引率

0.00%

发文量